ABSTRACT
Background: Neuropathy is one of the most common complications affecting individuals with diabetes mellitus. The best evidence indicates that the etiology of neuropathy is multifactorial and is a key area of current research. Hence, this study was undertaken to test the hypothesis of alteration in MNCV (motor nerve conduction velocity) of nerves before the actual manifestation of neuropathy in type II diabetic patients and also to analyze the effect of smoking on MNCV in diabetic subjects. Methods: In the present study, 120 diagnosed diabetics were taken as cases while 30 non diabetic healthy subjects were taken as controls. Case group was divided into diabetic non-smokers and diabetic smokers. Diabetic smokers were further subdivided into light, moderate and heavy smokers, according to smoking index. After detailed history and physical examination MNCV of median and ulnar nerve in upper limb and common peroneal nerve in lower limb was performed. Result: The MNCV of median and ulnar nerves in upper limb showed no significant bilateral decreased in diabetic non-smokers and subgroup of diabetic smokers when compared with control. However, there was a significant bilateral decrease in MNCV of common peroneal nerves in the lower limb of diabetic heavy smokers when compared with control. A negative, but statistically non-significant correlation was found between MNCV and smoking index. The decrease in MNCV was dependent on smoking index by 3%, 1%, 1%, 1%, 3% and 1% in median nerve (right), median nerve (left), ulnar nerve (right), ulnar nerve (left), common peroneal nerve (right) and common peroneal nerve (left) respectively. Conclusion: The present study indicates that MNCV is more resistant to hyperglycemia induced local metabolic and microvascular changes. However, the coalition of diabetes and smoking can augment their effects many folds and can lead to motor neuropathy, reiterating the fact that smoking itself is an independent risk factor for diabetic neuropathy.
ABSTRACT
Background: Drugs for liver ailments have been important in research, but still the number of drugs acting on various hepatic diseases is very limited. This study, for the fi rst time, evaluates the hepatoprotective activity of aqueous extract of the roots of Valeriana Wallichii in albino rats. Methods: The hepatotoxicity was induced by CCl4. Animals were divided into 5 groups of 6 animals each. Group I (Normal control) was given only distilled water. Group II (Negative control)was administered CCl4 for 7 days while Group III (Positive control) was given silymarin and CCl4 for 7 days. The test groups (Group IV & V) were given an aqueous extract of roots of V. Wallichii in a dose of 300 mg and 500 mg/kg, respectively. The animals were sacrifi ced on 8 days and blood was collected for biochemical analysis (aspartate aminotransferase [AST], alanine transaminase (ALT) and alkaline phosphatase). Liver tissue was extracted for histopathological examination and in vivo antioxidant tests Catalase [CAT], glutathione and malondialdehyde. The extract was also subjected to in vitro antioxidant tests (Total reducing power and total phenolic content). Results: The test extracts in the dose of 500 mg/kg were shown a signifi cant decrease in the levels of AST and ALT (p>0.05) and CAT activity. 300 mg/kg dose of extract showed minimal hepatoprotection. The fi ndings were confi rmatory to histopathology. Conclusion: The aqueous extract of roots of V. Wallichii in a dose of 500 mg/kg offers partial protection against hepatotoxicity produced by CCl4 in albino rats.